Ian Shakil - 12 Apr 2024 Form 4 Insider Report for Augmedix, Inc.

Signature
/s/ Todd Holvick, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
12 Apr 2024
Net transactions value
-$57,782
Form type
4
Filing time
15 Apr 2024, 21:15:05 UTC
Previous filing
11 Apr 2024
Next filing
16 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUGX Common Stock Options Exercise $16,808 +19,544 +651% $0.8600 22,544 12 Apr 2024 Direct F1
transaction AUGX Common Stock Sale $74,590 -19,544 -87% $3.82 3,000 12 Apr 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUGX Stock Option (Right to Buy) Options Exercise $0 -19,544 -4.1% $0.000000 456,449 12 Apr 2024 Common Stock 19,544 $0.8600 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades ranging from $3.8000 to $3.9300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Fully vested.